NOVEL PHARMACEUTICAL FORMULATIONS CONTAINING INDIRUBIN AND DERIVATIVES THEREOF AND METHODS OF MAKING AND USING THE SAME
申请人:Phosphorex, Inc.
公开号:EP3600259A1
公开(公告)日:2020-02-05
US8084621B2
申请人:——
公开号:US8084621B2
公开(公告)日:2011-12-27
[EN] NOVEL PHARMACEUTICAL FORMULATIONS CONTAINING INDIRUBIN AND DERIVATIVES THEREOF AND METHODS OF MAKING AND USING THE SAME<br/>[FR] NOUVELLES FORMULATIONS PHARMACEUTIQUES CONTENANT DE L'INDIRUBINE ET DES DÉRIVÉS DE CELUI-CI ET PROCÉDÉS DE FABRICATION ET D'UTILISATION DE CELLES-CI
申请人:PHOSPHOREX INC
公开号:WO2018183631A1
公开(公告)日:2018-10-04
The invention described herein provides various indirubin compositions for treating diseases.
3-Pyrrolo[b]Cyclohexylene-2-Dihydroindolinone Derivatives and Uses Thereof
申请人:Tang Feng
公开号:US20100160318A1
公开(公告)日:2010-06-24
3-pyrrolo[b]cyclohexylene-2-dihydro-indolinone derivatives of formula (I) or their pharmaceutically acceptable salts and uses thereof. The intermediates of formula (II) for preparing the above compounds. The bioassay shows that the above compounds and their pharmaceutically acceptable salts can modulate the activity of protein kinases (PKs), inhibit the activity of tyrosine kinases (PTKs) and inhibit many kinds of tumor cells as well as.
公式(I)的3-吡咯[ b ]环己烯-2-二氢吲哚酮衍生物或其药用盐及其用途。用于制备上述化合物的公式(II)的中间体。生物测定表明,上述化合物及其药用盐可以调节蛋白激酶(PKs)的活性,抑制酪氨酸激酶(PTKs)的活性,并抑制多种类型的肿瘤细胞。